Skip to main content
Premium Trial:

Request an Annual Quote

Moderna Reports Efficacy Among Adolescents

Moderna's SARS-CoV-2 vaccine is effective among adolescents, NPR reports.

The company announced that its mRNA-based vaccine had an efficacy of 93 percent in preventing COVID-19 among 12- to 17-year-olds. Its trial included 3,732 adolescents, two-thirds of whom received the vaccine and one-third of whom received a placebo. Four cases of COVID-19 occurred in the placebo group and none in the vaccine group using the same disease criteria the company used for its adult trial and when a more stringent definition that encompasses milder disease, the vaccine had a 93 percent efficacy.

According to NPR, Moderna CEO Stéphane Bancel says the company plans to submit its results to the US Food and Drug Administration and other regulators next month. The Verge notes that the Moderna vaccine is currently authorized for people over the age of 18.

Pfizer and BioNTech similarly reported in late March that their vaccine was effective in preventing COVID-19 among adolescents and the FDA granted them Emergency Use Authorization for that age group earlier this month.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.